Aurobindo Pharma gets USFDA nod for Repaglinide tablets

Aurobindo Pharma has received final approval from the US Food & Drug Administration to manufacture and market generic Repaglinide tablets that are used as an adjunct to diet in diabetic patients.

The approval is for multiple strengths of the drug in 0.5mg, 1mg and 2mg. The product is ready for launch, the company said in a statement.

The Repaglinide tablets are the generic equivalent of Novo Nordisk Prandin Tablets. These are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, it added.

Quoting IMS data, the company said the market size of the product is estimated to be USD 274 million for the twelve months ending November 2013.

Aurobindo now has a total of 189 abbreviated new drug approvals from USFDA.

Shares of Aurobindo Pharma were trading at Rs 433 per scrip in the afternoon trade, down 0.74 per cent from previous close, on the BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Need to rein in profligate promoters in low margin airline business

    With the media and industry searchlight trained hard on SpiceJet, it is easy to forget that it may be, at worst, a symptom, not the real malaise itsel

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Roopen Roy

Why do we shoot, load and then aim?

There is a joke about what Indians would do in ...

Zehra Naqvi

When humanity died, bestiality prevailed

The terrorist attack that killed 132 children in Peshawar has ...

Dharmendra Khandal

Protecting jungle cats is vital

In what can only be called a cat night, we ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture